NEW YORK, March 29, 2019 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been
filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to
request that the court appoint you as lead plaintiff.
Lexicon Pharmaceuticals, Inc. (NASDAQGS: LXRX)
Class Period: March 11, 2016 to January 17, 2019
Lead Plaintiff Deadline: April 1, 2019
The lawsuit alleges that Lexicon Pharmaceuticals, Inc. made materially false and/or misleading statements and/or
failed to disclose that: (i) the data from Lexicon’s Phase 3 clinical trials assessing the safety and efficacy of Sotagliflozin in
treating type 1 diabetes were not as positive as Lexicon represented; (ii) the health risks posed by Sotagliflozin were severe
enough to threaten its U.S. Food & Drug Administration approval prospects; and (iii) as a result, Lexicon’s public statements were
materially false and misleading at all relevant times.
Get additional information about the LXRX lawsuit: http://www.kleinstocklaw.com/pslra-1/lexicon-pharmaceuticals-inc-loss-submission-form?wire=3
Uxin Limited (NASDAQGS: UXIN)
Class Period: Pursuant and/or traceable to the Company’s Registration Statement and Prospectus issued in connection with the June
27, 2018 initial public offering
Lead Plaintiff Deadline: April 12, 2019
The Registration Statement was materially false and misleading and omitted to state that: (1) Uxin was likely to
stop providing complementary services such as inspections to its customers; (2) instead, Uxin would connect consumers to dealers
who would provide such complementary services; (3) as a result, Uxin’s 2B business would be materially impacted; and (4)
consequently, Defendants’ statements in the Registration Statement regarding Uxin’s business, operations, and prospects, were
materially false and/or misleading.
Get additional information about the UXIN lawsuit: http://www.kleinstocklaw.com/pslra-1/uxin-limited-loss-submission-form?wire=3
AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO)
Class Period: August 4, 2016 to January 31, 2019
Lead Plaintiff Deadline: April 26, 2019
The complaint alleges AVEO Pharmaceuticals, Inc. made materially false and/or misleading statements and/or
failed to disclose that: (i) the TIVO‑3 trial was inadequately designed to address the OS concerns regarding AVEO’s lead candidate
drug, tivozanib, from the TIVO-1 trial presented in June 2013; (ii) tivozanib had insufficient survival data to meet FDA approval
following its initial 2013 rejection; (iii) this lack of sufficient survival data would put tivozanib at greater risk of delayed
FDA approval; and (iv) as a result, AVEO’s public statements were materially false and misleading at all relevant times.
Get additional information about the AVEO lawsuit: http://www.kleinstocklaw.com/pslra-1/aveo-pharmaceuticals-inc-loss-submission-form?wire=3
Amarin Corporation (NASDAQGM: AMRN)
Class Period: September 24, 2018 to November 9, 2018
Lead Plaintiff Deadline: April 23, 2019
According to the complaint, Amarin Corporation allegedly made materially false and/or misleading statements
and/or failed to disclose that: (1) the top-line results Amarin touted about its REDUCE-IT trial for Vascepa were not as positive
as the company represented; (2) the placebo given to patients in the control arm of REDUCE-IT may have increased the incidence of
cardiovascular events in those patients; (3) as a result, Amarin's public statements were materially false and misleading at all
relevant times.
Get additional information about the AMRN lawsuit: http://www.kleinstocklaw.com/pslra-1/amarin-corporation-loss-submission-form?wire=3
Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or
obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J.
Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud
throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
